Literature DB >> 7229031

Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: A clinical manifestation of selective down-regulation of granulocyte responses to C5adesarg.

K M Skubitz, P R Craddock.   

Abstract

The transient granulocytopenia of hemodialysis results indirectly from plasma complement activation by dialyzer cellophane membranes. The C5a(desarg) so produced can induce reversible granulocyte aggregation in vitro and in vivo, and we hypothesized that the pulmonary leukostasis responsible for the granulocytopenia results from embolization of aggregates formed under the influence of C5a(desarg) produced in the dialyzer. These studies were designed to measure C5a(desarg) generation during dialysis by granulocyte aggregometry and to determine the reason for the transience of the leukostasis. C5a(desarg) generation was equally evident throughout dialysis, persisting well after granulocytopenia had reversed, and dialyzer-induced complement activation was insufficient to produce significant depletion of plasma complement titers. That granulocyte deactivation might be responsible for the transience was suggested by the absence of the usual granulocytopenia in a patient with uniquely high levels of C5a(desarg) in his predialysis plasma. Granulocytes drawn from seven stable uremic patients after granulocytopenia had reversed exhibited a dose-related, selective and irreversible refractoriness to stimulation with C5a(desarg), but their responses to n-formyl-Met-Leu-Phe remained normal. Identical deactivation was produced in normal cells by short- or long-term exposure of C5a(desarg) in vitro. These studies suggest that C5a(desarg) is indeed generated by the dialyzer throughout hemodialysis and that the transience of the leukostasis and granulocytopenia is due to selective down-regulation of cellular responses to C5a(desarg)-a phenomenon that hitherto has been described only in vitro and that may be important in limiting the deleterious effects of adherent granulocytes on the endothelium in patients with intravascular complement activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7229031      PMCID: PMC370704          DOI: 10.1172/jci110166

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.

Authors:  T Sacks; C F Moldow; P R Craddock; T K Bowers; H S Jacob
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

2.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 3.  Complement deficiency states.

Authors:  V Agnello
Journal:  Medicine (Baltimore)       Date:  1978-01       Impact factor: 1.889

4.  Digital integration of granulocyte aggregation responses. A simple and reproducible method for the quantitation of granulocyte adhesiveness.

Authors:  P R Craddock; J G White; D J Weisdorf; D E Hammerschmidt
Journal:  Inflammation       Date:  1980-12       Impact factor: 4.092

5.  Effect of intravascular complement activation on granulocyte adhesiveness and distribution.

Authors:  J T O'Flaherty; P R Craddock; H S Jacob
Journal:  Blood       Date:  1978-04       Impact factor: 22.113

6.  Immune complexes in congenital and natal cytomegalovirus infections of man.

Authors:  S Stagno; J E Volanakis; D W Reynolds; R Stroud; C A Alford
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

7.  Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states.

Authors:  D E Hammerschmidt; J G White; P R Craddock; H S Jacob
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

8.  Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes.

Authors:  D E Chenoweth; T E Hugli
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

9.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis.

Authors:  P R Craddock; J Fehr; K L Brigham; R S Kronenberg; H S Jacob
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

10.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

Authors:  P R Craddock; J Fehr; A P Dalmasso; K L Brighan; H S Jacob
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  15 in total

1.  Impermeant stilbene disulfonic acids block chemotactic peptide receptor function on human granulocytes.

Authors:  K M Skubitz; G M Vercellotti; C S Greenberg; J W Eaton
Journal:  Inflammation       Date:  1989-02       Impact factor: 4.092

Review 2.  The role of complement in immune clearance of blood cells.

Authors:  U E Nydegger; M D Kazatchkine
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Regulation of neutrophil migratory function in burn injury by complement activation products.

Authors:  J S Solomkin; R D Nelson; D E Chenoweth; L D Solem; R L Simmons
Journal:  Ann Surg       Date:  1984-12       Impact factor: 12.969

4.  Subnormal activation of phagocytes by complement in chronic inflammatory bowel disease? Neutrophil chemotaxis to complement split product C5a.

Authors:  J Elmgreen
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

5.  Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent.

Authors:  J Elmgreen; T M Hansen
Journal:  Ann Rheum Dis       Date:  1985-08       Impact factor: 19.103

6.  Alterations in activities of anaphylatoxin inactivator and chemotactic factor inactivator during hemodialysis.

Authors:  J R McCormick; D L Kreutzer; H J Keating; J Hupp; A Despins; M Moore
Journal:  Am J Pathol       Date:  1982-12       Impact factor: 4.307

7.  Changes in neutrophil surface phenotype during hemodialysis.

Authors:  K M Skubitz; J Butterfield; K Ma; A P Skubitz
Journal:  Inflammation       Date:  1998-12       Impact factor: 4.092

8.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

Authors:  K M Skubitz; P R Craddock; D E Hammerschmidt; J T August
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

9.  Endotoxin-induced selective dysfunction of rabbit polymorphonuclear leukocytes in response to endogenous chemotactic factors.

Authors:  K T Hartiala; L Langlois; I M Goldstein; J T Rosenbaum
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

10.  Biochemical and functional characterization of the leucocyte tyrosine phosphatase CD45 (CD45RO, 180 kD) from human neutrophils. In vivo upregulation of CD45RO plasma membrane expression on patients undergoing haemodialysis.

Authors:  R Pulido; V Alvarez; F Mollinedo; F Sánchez-Madrid
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.